Patent intelligence · WO
WO 2025242584
FORMULATION DE CAPSULE DE GÉLATINE MOLLE STABLE POUR ÉLINZANÉTANT
FORMULATION DE CAPSULE DE GÉLATINE MOLLE STABLE POUR ÉLINZANÉTANT
Patent details — WO 2025242584
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Nov 27, 2025
- Expiration
- Nov 22, 2045
- Applicant
- BAYER CONSUMER CARE AG [CH]
- CPC classes
- A61K 9/ 48 A I, A61K 47/ 10 A I, A61K 47/ 14 A I, A61K 47/ 22 A I
Quick answer
WO 2025242584 (FORMULATION DE CAPSULE DE GÉLATINE MOLLE STABLE POUR ÉLINZANÉTANT) is held by BAYER CONSUMER CARE AG [CH]. Status: granted. Granted Nov 27, 2025. Expires Nov 22, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BAYER CONSUMER CARE AG [CH]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 48 A I, A61K 47/ 10 A I, A61K 47/ 14 A I, A61K 47/ 22 A I, A61K 47/ 26 A I, A61K/4710
More from BAYER CONSUMER CARE AG [CH]
Related pharmaceutical patents in our USPTO index.
-
WO 2026112109
TECHNOLOGIE DE PLATEFORME DE GRANULATION PAR VOIE HUMIDE POUR FABRIQUER DES COMPRIMÉS/ARTICLES À MÂCHER MOUS
granted -
WO 2026106858
FORMULATIONS ET PROCÉDÉS POUR MAINTENIR UNE SUSPENSION ET UNE VIABILITÉ DE CELLULES
granted -
EP 4741400
MULTIMERE MANGANKONTRASTMITTEL
granted -
WO 2026068294
PROCESSUS DE NANOENSEMENCEMENT AMÉLIORÉ
granted -
WO 2026047020
FORMES CRISTALLINES D'INHIBITEURS DE HER2/MUTEGFR ET LEUR PROCÉDÉ DE PRÉPARATION
granted -
WO 2026047022
FORME POSOLOGIQUE PHARMACEUTIQUE SOLIDE ET STABLE COMPRENANT UNE FORME CRISTALLINE D'UN INHIBITEUR DE HER2/MUTEGFR ET SA MÉTHODE DE PRÉPARATION
granted -
US 20260051027
GENERATION OF SYNTHETIC CONTRAST-ENHANCED RADIOLOGICAL IMAGES
granted -
WO 2026032865
SEL D'UN INHIBITEUR DE SOS-1
granted
Frequently asked questions
What is US patent 2025242584?
WO 2025242584 (FORMULATION DE CAPSULE DE GÉLATINE MOLLE STABLE POUR ÉLINZANÉTANT) is held by BAYER CONSUMER CARE AG [CH]. Status: granted. Granted Nov 27, 2025. Expires Nov 22, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2025242584?
BAYER CONSUMER CARE AG [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2025242584 expire?
Our index shows an expiration date of Nov 22, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.